The product I’ve been talking about the most is a combination of the drugs cabotegravir and rilpivirine.
Cabotegravir is an integrase inhibitor, in the same class as dolutegravir (in products like Triumeq, Dovato, Juluca ) and bictegravir (in Bictarvy).
Ripivirine (in Complera and Juluca) is a non-nucleoside analogue in the same class as drugs like Efavirenz (in Atripla), Etravirine (Intellence) and Doravirine (Pilfeltro).
The medical community was really expecting the Food and Drug Administration to approve this long-acting therapy for once-monthly dosing in December; a sort of Christmas present.
The drug preparation is…
